Urinary-Based Markers for Bladder Cancer Detection
BackgroundThe use of urine markers for diagnosis and surveillance has been a topic of broad interest and ongoing controversies in the management of patients with bladder cancer. There has been a constant quest for markers that demonstrate clinical utility. AimIn the framework of the International C...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-10-01
|
| Series: | Société Internationale d’Urologie Journal |
| Subjects: | |
| Online Access: | https://siuj.org/index.php/siuj/article/view/54/11 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849407191251943424 |
|---|---|
| author | Tilman Todenhöfer, Michele Lodde, Kim van Kessel, Renate Pichler, Antonia Vlahou, Yair Lotan |
| author_facet | Tilman Todenhöfer, Michele Lodde, Kim van Kessel, Renate Pichler, Antonia Vlahou, Yair Lotan |
| author_sort | Tilman Todenhöfer, Michele Lodde, Kim van Kessel, Renate Pichler, Antonia Vlahou, Yair Lotan |
| collection | DOAJ |
| description | BackgroundThe use of urine markers for diagnosis and surveillance has been a topic of broad interest and ongoing controversies in the management of patients with bladder cancer. There has been a constant quest for markers that demonstrate clinical utility.
AimIn the framework of the International Consultation on Urological Diseases 2019 on Molecular Biomarkers in Urologic Oncology, a comprehensive review of literature on urinary biomarkers for bladder cancer has been performed.
ResultsCurrently available urinary markers include protein-based markers, RNA-based markers, and DNA-based markers. The introduction of high-throughput analysis technologies provides the opportunity to assess multiple parameters within a short period of time, which is of interest for RNA-based, DNA-based, and protein-based marker systems. A comprehensive analysis of molecular alterations in urine samples of bladder cancer patients may be of interest not only for diagnosis and surveillance but also for non-invasive longitudinal assessment of molecular, potentially therapy-relevant, alterations. However, most systems lack prospective validation within well-designed trials and have not been broadly implemented in daily clinical practice.
ConclusionsBecause of limited data from prospective trials, the routine use of any urine marker except cytology is not considered as standard of care in international guidelines. There is an urgent need for prospective trials of urine markers to answer specific clinical questions. |
| format | Article |
| id | doaj-art-45cf6f7d7a0743049da4f2ed15721c61 |
| institution | Kabale University |
| issn | 2563-6499 |
| language | English |
| publishDate | 2020-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Société Internationale d’Urologie Journal |
| spelling | doaj-art-45cf6f7d7a0743049da4f2ed15721c612025-08-20T03:36:10ZengMDPI AGSociété Internationale d’Urologie Journal2563-64992020-10-0111496110.48083//KQGP2151Urinary-Based Markers for Bladder Cancer DetectionTilman Todenhöfer, Michele Lodde, Kim van Kessel, Renate Pichler, Antonia Vlahou, Yair LotanBackgroundThe use of urine markers for diagnosis and surveillance has been a topic of broad interest and ongoing controversies in the management of patients with bladder cancer. There has been a constant quest for markers that demonstrate clinical utility. AimIn the framework of the International Consultation on Urological Diseases 2019 on Molecular Biomarkers in Urologic Oncology, a comprehensive review of literature on urinary biomarkers for bladder cancer has been performed. ResultsCurrently available urinary markers include protein-based markers, RNA-based markers, and DNA-based markers. The introduction of high-throughput analysis technologies provides the opportunity to assess multiple parameters within a short period of time, which is of interest for RNA-based, DNA-based, and protein-based marker systems. A comprehensive analysis of molecular alterations in urine samples of bladder cancer patients may be of interest not only for diagnosis and surveillance but also for non-invasive longitudinal assessment of molecular, potentially therapy-relevant, alterations. However, most systems lack prospective validation within well-designed trials and have not been broadly implemented in daily clinical practice. ConclusionsBecause of limited data from prospective trials, the routine use of any urine marker except cytology is not considered as standard of care in international guidelines. There is an urgent need for prospective trials of urine markers to answer specific clinical questions.https://siuj.org/index.php/siuj/article/view/54/11urinebiomarkerssurveillancescreeninghematuriaurothelial carcinoma |
| spellingShingle | Tilman Todenhöfer, Michele Lodde, Kim van Kessel, Renate Pichler, Antonia Vlahou, Yair Lotan Urinary-Based Markers for Bladder Cancer Detection Société Internationale d’Urologie Journal urine biomarkers surveillance screening hematuria urothelial carcinoma |
| title | Urinary-Based Markers for Bladder Cancer Detection |
| title_full | Urinary-Based Markers for Bladder Cancer Detection |
| title_fullStr | Urinary-Based Markers for Bladder Cancer Detection |
| title_full_unstemmed | Urinary-Based Markers for Bladder Cancer Detection |
| title_short | Urinary-Based Markers for Bladder Cancer Detection |
| title_sort | urinary based markers for bladder cancer detection |
| topic | urine biomarkers surveillance screening hematuria urothelial carcinoma |
| url | https://siuj.org/index.php/siuj/article/view/54/11 |
| work_keys_str_mv | AT tilmantodenhofermicheleloddekimvankesselrenatepichlerantoniavlahouyairlotan urinarybasedmarkersforbladdercancerdetection |